FDAsafety guidance66% confidence
Internet Pharmacy Warning Letters
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Hikma Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Rogue online pharmacies offer potentially dangerous prescription drugs to U.S. consumers. FDA has issued warning letters informing the website operators that they are engaged in illegal activity in violation of the U.S.
Supporting Context
- Therapeutic area
- Cardiovascular · Anticoagulant
- Sub-indication
- General
Related signal: FDA Accepts Supplemental NDA for Argatroban by Hikma Pharma